Chile’s Ministry of Health (Minsal) launched its 2026 Vaccination and Immunization Campaign on March 1st, aiming to protect the population against key respiratory viruses, including influenza, COVID-19, pneumococcus, whooping cough, and, significantly, the respiratory syncytial virus (RSV). This year’s campaign places particular emphasis on RSV, a common virus that can cause severe illness, especially in infants. Understanding who should be vaccinated and recognizing the symptoms of RSV are crucial steps in safeguarding public health this season.
While RSV can affect people of all ages, it poses the greatest risk to infants under 12 months vintage. The virus is a leading cause of respiratory illnesses in this age group, particularly during the autumn and winter months. Government officials have highlighted the success of recent immunization efforts against RSV, noting that no deaths were recorded in children under one year of age in both 2024 and 2025. This represents a significant improvement in public health outcomes.
The positive trend extends to hospitalizations as well. Respiratory-related hospitalizations among infants decreased by 61% in 2024 and 62% in 2025 compared to 2023, the year prior to the widespread implementation of the monoclonal antibody treatment for RSV. These figures underscore the effectiveness of preventative measures in mitigating the impact of the virus. The Ministry of Health is continuing to monitor the situation and adapt its strategies as needed.
Who Should Receive the RSV Immunization?
The 2026 campaign outlines specific groups eligible for RSV immunization, including newborns, infants born since October 1, 2024, and infants considered at high risk. Premature babies—those born before 32 weeks of gestation—or those with a birth weight of less than 1.5 kilograms are also prioritized. Minsal has identified other infants at risk who will be eligible for the immunization. More detailed information on eligibility criteria can be found on the Minsal website.
The use of a monoclonal antibody to protect against RSV is a relatively new approach, and Chile is among a small number of countries globally that have adopted this strategy. This proactive measure demonstrates the country’s commitment to protecting its most vulnerable population.
Recognizing the Symptoms of RSV
Early detection of RSV symptoms is vital for prompt medical attention and preventing complications. Parents and caregivers should be vigilant for signs such as unusual tiredness or a decrease in the child’s typical energy levels. A loss of appetite or refusal to eat can also be an indicator. Other symptoms to watch for include persistent cough, headache, irritability, and agitation. These symptoms, while not exclusive to RSV, warrant a consultation with a healthcare professional.
It’s vital to remember that symptoms can vary in severity. Some infants may experience mild, cold-like symptoms, while others may develop more serious complications like bronchiolitis or pneumonia. If a child exhibits difficulty breathing, rapid breathing, or a bluish tint to the skin, immediate medical attention is crucial.
The Ministry of Health encourages all eligible individuals to accept advantage of the vaccination campaign. Protecting against RSV, alongside other respiratory viruses, is a key component of maintaining public health and ensuring the well-being of the community. The campaign also includes vaccinations against influenza, COVID-19, pneumococcus, and whooping cough, offering comprehensive protection against a range of respiratory illnesses.
The success of Chile’s RSV immunization program serves as a model for other nations seeking to reduce the burden of this common, yet potentially serious, virus. Continued monitoring and evaluation of the campaign’s impact will be essential to refine strategies and optimize outcomes in the years to come.
The next update from Minsal regarding the vaccination campaign is expected in April 2026, when preliminary data on vaccination rates and initial impact assessments will be released. For the most up-to-date information and resources, please visit the Minsal website.
Have thoughts on this story? Share your comments below and assist us continue to provide valuable health information to our readers.
